Chest malignant tumor
Conditions
Interventions
Control group:125I need implantation therapy
Study group:125I need implantation therapy combined with personalized neoantigen peptides once a week, 12 weeks for a course of treatment
Sponsors
Tianjin Beichen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Patients with stage III/IV breast malignant tumors with an estimated survival of more than 3 months; 2.There are lesions that can be implanted with 125I seed implantation; 3.PS score 3-4; 4.More than one gene mutation is can be used to design personalized neoantigen peptides; 5.No previous neoantigen immunotherapy.
Exclusion criteria
Exclusion criteria: 1.Pregnancy or lactation woman; 2.Patients with known or suspected autoimmune disease or other complicated immune system disease; 3.Patients with liver and kidney dysfunction, severe heart disease, coagulation dysfunction and hematopoietic impairment; 4.Patients with systemic infections; 5.Any disease, treatment, laboratory examination abnormality or medical history that may affect the participants' inability to participate in the entire study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunological indexes;disease control rate;Progression-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactXueming Du
Tianjin Beichen Hospital
Outcome results
None listed